Iran Thalassemia Society v. Office of Foreign Assets Control

CourtDistrict Court, D. Oregon
DecidedMay 1, 2023
Docket3:22-cv-01195
StatusUnknown

This text of Iran Thalassemia Society v. Office of Foreign Assets Control (Iran Thalassemia Society v. Office of Foreign Assets Control) is published on Counsel Stack Legal Research, covering District Court, D. Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Iran Thalassemia Society v. Office of Foreign Assets Control, (D. Or. 2023).

Opinion

IN THE UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF OREGON

IRAN THALASSEMIA SOCIETY, a No. 3:22-cv-01195-HZ nonprofit organization; EB HOME, a nonprofit organization; H.K., an individual; A.M., an OPINION & ORDER individual; S.N., an individual; M.M., an individual; FZ.H., an individual; F.E., an individual; and NO CHILD SHOULD SUFFER, a nonprofit organization,

Plaintiffs,

v.

OFFICE OF FOREIGN ASSETS CONTROL; JANET YELLEN, in her official capacity as Secretary of the Treasury; and ANDREA GACKI, in her official capacity as Director of the Office of Foreign Assets Control,

Defendants.

Thomas H. Nelson Thomas H. Nelson & Associates 20820 E. Glacier View Road Zigzag, OR 97049 Brandon Mayfield The Law Office of Brandon Mayfield 14631 SW Millikan Way Beaverton, OR 97003

Attorneys for Plaintiff

Brian M. Boynton Principal Deputy Assistant Attorney General Alexander K. Haas Director, Federal Programs Branch Diane Kelleher Assistant Director, Federal Programs Branch Stephen M. Elliott Stuart J. Robinson United States Department of Justice Civil Division, Federal Programs Branch 1100 L St. NW Washington, D.C. 20005

Attorneys for Defendants

HERNÁNDEZ, District Judge: Defendants move to dismiss Plaintiffs’ Second Amended Complaint (“SAC”) in this suit challenging the “maximum pressure” sanctions imposed on Iran by the Office of Foreign Assets Control (“OFAC”). For the following reasons, the Court grants Defendants’ motion. BACKGROUND Plaintiffs are an Iranian organization representing the interests of individuals in Iran suffering from thalassemia, a genetic blood disorder; an Iranian organization representing the interests of individuals in Iran suffering from epidermolysis bullosa (“EB”), a genetic skin disorder; six Iranian citizens suffering from EB; and an Oregon domestic nonprofit formed to support Iranian children impacted by the United States Government’s sanctions on Iran. Plaintiffs assert that OFAC’s “maximum pressure” sanctions on Iran are unlawfully preventing necessary medical supplies and medications from reaching individuals in Iran suffering from thalassemia and EB. I. The Sanctions

The SAC alleges that on May 8, 2018, then-President Donald Trump announced the United States’ withdrawal from the Joint Comprehensive Plan of Action (“JCPOA”), a 2015 agreement to which the United States and Iran were parties. SAC ¶ 15, ECF 26. At the same time, he announced both a re-imposition of economic sanctions that had been lifted as part of the JCPOA and new “maximum pressure” sanctions to pressure Iran into a new agreement. Id. Plaintiffs allege that authorized sanctions include imprisonment and fines of up to $1 million. Id. ¶ 16. They allege that these sanctions “ultimately targeted virtually the entire Iranian commercial banking sector.” Id. ¶ 17. They allege that as a result, “foreign banks ceased dealing with their blocked Iranian counterparts[.]” Id. Thus, transactions with Iranian businesses became “extremely difficult if not impossible.” Id. ¶ 18.

Plaintiffs allege that European businesses that had once been willing to do business in Iran, including those that provided humanitarian aid, terminated those agreements. Id. ¶ 20. Before OFAC imposed the “maximum pressure” sanctions on Iran, Plaintiffs could obtain the necessary medicines and medical supplies “through normal commercial channels.” Id. ¶ 2. After the “maximum pressure” sanctions were imposed, they could not. Id. ¶ 15. According to Plaintiffs, foreign banks and other financial institutions “fear that defendant OFAC will impose secondary sanctions upon them.” Id. ¶ 25. Plaintiffs explain that “[t]his fear is due in large part because of the uncertain scope and complexity of the maximum pressure sanctions, and also because the normal fees or commissions from acting as an intermediary bank are minimal.” Id. Plaintiffs allege that on October 25, 2019, OFAC announced that it intended to create a process to allow foreign banks to participate in the delivery of humanitarian aid to Iran without fear of secondary sanctions. SAC ¶ 26. They allege that the policy required participating financial institutions to provide extensive information to the U.S. Department of the Treasury

each month. Id. Plaintiffs allege that this amounts to a requirement that participating financial institutions “actively seek and turn over to OFAC intelligence information gleaned from espionage on Iranian customers of humanitarian aid.” Id. According to Plaintiffs, none of the foreign banks that previously facilitated delivery of humanitarian aid to the Iranian Plaintiffs chose to participate in this program. Id. ¶ 27. Plaintiffs assert that these third party entities will engage in the transactions again if the “maximum pressure” sanctions are lifted. Id. Plaintiffs also allege that because of the sanctions, Iran later “began relaxing its compliance with the terms of the JCPOA and repositioning its economic system away from Europe and the West and in close alignment with Eastern economic powers, initially with China, and more recently with Russia.” Id. ¶ 19.

II. The Plaintiffs Plaintiffs are individuals and organizations representing the interests of those in Iran who suffer from two genetic conditions: thalassemia and EB. The SAC explains that “[t]halassemia is a genetic blood disorder that is treated by blood transfusions.” SAC ¶ 22. Frequent blood transfusions “cause excess iron to be concentrated in the patient’s blood which, unless treated, can cause iron toxicity, compromise vital organs (heart, liver, spleen, endocrine system), and ultimately lead to death.” Id. The two most effective medications to treat this problem are Desferal and Jadenu, both of which are manufactured by Novartis Pharmaceutical, a Swiss company. Id. ¶¶ 1, 22. Before the “maximum pressure” sanctions were imposed, these medications were generally available in Iran. Id. ¶ 22. Since the advent of the “maximum pressure” sanctions, patients have had to rely on Desfonac, the Iranian version of the drug, which is less effective and has negative side effects. Id. Plaintiffs allege that “over 600 thalassemia patients have died unnecessarily” since the “maximum pressure” sanctions were announced

because they could not receive the necessary medication. SAC ¶¶ 4, 23. They allege that “[t]he annual mortality rate for afflicted Iranians suffering from thalassemia has jumped from 30-40 deaths per year to 150 deaths per year since imposition of the maximum pressure sanctions.” Id. ¶ 21. They allege that if the foreign medications became available again, most patients could fully recover. Id. ¶ 23. According to the SAC, the Iran Thalassemia Society is “an Iranian non-governmental organization formed in 1989 by a number of parents with children suffering from thalassemia major and physicians involved in the treatment of those patients.” SAC ¶ 7. The Secretary of the Society, Younos Arab, was born with thalassemia, as were all other members. Id. Plaintiffs allege that the lack of suitable iron-chelating drugs has frustrated the Society’s mission and

diverted its resources. Id. The SAC explains that “EB is a genetic skin disorder that causes the skin to become very fragile to the point that the slightest friction can cause blistering and open sores.” SAC ¶ 24. Mepilex, a specialized wound dressing, is the best treatment for these sores. Id. Mepilex is manufactured by Mölnlycke Health Care A.B. of Gothenberg, Sweden, and is not available from other sources. Id. According to the SAC, “Mölnlycke Health Care has announced publicly that it is not willing to sell its products to Iran because of OFAC’s illegal threats of sanctions.” Id. ¶ 5.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Chandler v. State Farm Mutual Automobile Insurance
598 F.3d 1115 (Ninth Circuit, 2010)
Mayfield v. United States
599 F.3d 964 (Ninth Circuit, 2010)
Baggett v. Bullitt
377 U.S. 360 (Supreme Court, 1964)
Asarco Inc. v. Kadish
490 U.S. 605 (Supreme Court, 1989)
Lujan v. Defenders of Wildlife
504 U.S. 555 (Supreme Court, 1992)
Kokkonen v. Guardian Life Insurance Co. of America
511 U.S. 375 (Supreme Court, 1994)
Federal Election Commission v. Akins
524 U.S. 11 (Supreme Court, 1998)
Utah v. Evans
536 U.S. 452 (Supreme Court, 2002)
Carrico v. City and County of San Francisco
656 F.3d 1002 (Ninth Circuit, 2011)
Maya v. Centex Corp.
658 F.3d 1060 (Ninth Circuit, 2011)
Clapper v. Amnesty International USA
133 S. Ct. 1138 (Supreme Court, 2013)
Corrie Ex Rel. Corrie v. Caterpillar, Inc.
503 F.3d 974 (Ninth Circuit, 2007)
Robinson v. United States
586 F.3d 683 (Ninth Circuit, 2009)
Lacano Investments, LLC v. Joe Balash
765 F.3d 1068 (Ninth Circuit, 2014)
Bernardo Mendia v. John Garcia
768 F.3d 1009 (Ninth Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Iran Thalassemia Society v. Office of Foreign Assets Control, Counsel Stack Legal Research, https://law.counselstack.com/opinion/iran-thalassemia-society-v-office-of-foreign-assets-control-ord-2023.